WuXi Biologics (Cayman) Inc. (WXIBF)
WuXi Biologics (Cayman) Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wuxi, JS, CN. The stock last traded at $5.85, up 27.17% on the session, giving a market capitalisation of $24.24B. On trailing twelve-month figures it carries a trailing P/E of 33.00, a net margin of 22.5%. Its beta of 0.60 implies it has historically moved less than the broad market.
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives. Furthermore, it provides clinical and manufacturing support for biologics, manufactures and distributes medical products, serves as a contract development and manufacturing organization (CDMO) for vaccines, and functions as a material supplier. WuXi Biologics maintains significant strategic collaborations with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc. The organization, founded in 2014, is headquartered in Wuxi, China.
WuXi Biologics (Cayman) Inc. is most often compared with the following Healthcare names: